Medtech | Ophthalmology Innovation Source

Ocular Therapeutix Starting to Sprint

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 016″] Prior to starting Ocular Therapeutix, Amar Sawhney, already a successful medtech entrepreneur, was a bit concerned about the unique challenges posed by the ophthalmology sector. Today, with the commercial launch of its ReSure Sealant underway and a successful IPO completed, Sawhney says he’s more than confident in the plan to…

Alcon’s Head Jeff George Lays Out Vision

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 015″] Jeff George, President & Global Head of Alcon, shares his optimism for the ophthalmology sector with attendees at the recent Ophthalmology Innovation Summit in Chicago. George explained where Alcon was putting research and development dollars (spoiler, one involves Google.) He also identified what he saw as intriguing companies and technologies…

Eye Companies Helping Health Care Stand Out

Healthcare stocks are outperforming the indices, and ophthalmic companies are helping to fuel a large part of that growth, Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking for J.P. Morgan, told attendees at the Ophthalmology Innovation Summit in Chicago. “Healthcare has outperformed most other sectors, and it has been primarily driven…

Digital Health Companies Poised to Grow

When the OIS started its digital showcase in 2012, there was only one company presenting in the category. “Today there are six—evidence that this area has huge momentum,” said Gilbert H. Kliman, MD, OIS Co-Chair and Managing Director of InterWest Partners. Mobile health platforms and applications lead the pack, with new approaches to diagnosis, patient…

How Thoughtful Consolidation Can Benefit Ophthalmology

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 014″] At the recent Ophthalmology Innovation Summit in Chicago, Jeff George, President & Global Head of Alcon; David E.I. Pyott, CEO of Allergan; Murthy V. Simhambhatla, PhD, President of Abbott Medical Optics; and

How Alcon & Google Could Change The Contact Lens

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 013″] At the recent Ophthalmology Innovation Summit in Chicago, Google and Alcon executives shared the origins and potential outcomes of the partnership between the two companies. Initially, they hope to develop a contact lens capable of measuring the wearer’s glucose levels but future applications are even bolder.

How Alcon and Google Could Change The Contact Lens

Moderator: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health. View Full Profile Panelists: Brian P. Otis, PhD Dr. Brian Otis is the founder of Google [x]’s smart contact lens…

NASA-Backed Entity Enlists Industry To Battle Eye Disorders Caused By Space Travel

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 012″] In this week’s podcast, Dorit B. Donoviel, PhD, Deputy Chief Scientist and Industry Forum Lead of the National Space Biomedical Research Institute, and Randy McDonald, Founder and President of the Magnum Group, expand on an announcement made at last week’s Ophthalmology Innovation Summit. A new joint effort between industry and…

Dirk Sauer Oversees Novartis’ Promising & Productive Ophthalmic Pipeline

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 011″] As Global Head of Development Franchise Ophthalmics at Novartis, Dirk Sauer has overseen the development of Novartis’ blockbuster Lucentis. Now, his focus is on the pharmaceutical giant’s pipeline of retina compounds, including many in the early stages. Hear how Sauer views innovation, both inside and outside of Novartis. Podcast Guest…

How Do You Talk to an Angel?

Ophthalmic Surgeon, Eric D. Kanter, MD, of Retina-Vitreous Consultants, balances his work at his busy New Jersey practice with his commitments as a principal member of Mid Atlantic Bio Angels. Members of MABA invest between $250,000 to $500,000 in life science start-ups of all types. Submissions for review have included ophthalmic drug, various types of…

Gobiquity Goes Big In Mobile Imaging Diagnostics

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 010″] Gobiquity CEO Michael Brownell breaks down the mobile ophthalmology market from the viewpoint of a start-up that’s set to change how kids are diagnosed with amblyopia, the number one cause of vision loss in kids. Podcast Guest Michael Brownell Michael Brownell joined Gobiquity as CEO in 2012, with prior experience…

Kliman: Ophthalmology Is A “Leading Franchise” At InterWest

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 006″] OIS Co-Chair, Gil Kliman, MD, Managing Director at InterWest Partners, delivers insight on his firm’s decision to concentrate on ophthalmology fifteen years ago and shares the many lessons he’s learned during that time. Podcast Guest Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest…